Distribution of the Major Cytochrome P450 (CYP) 2C9 Genetic Variants in a Saudi Population

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 2, 2011, Pages 111-114

  Mirghani, Rajaa A ^a   Chowdhary, Gulnaz ^a   Elghazali, Gehad ^a,b,c  

^a KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

^c University of Shendi   (Sudan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; GENOMIC DNA;

ADULT; ARTICLE; ENZYME LOCALIZATION; FEMALE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SAUDI ARABIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENETIC VARIATION; GENETICS, POPULATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; SAUDI ARABIA; SUBSTRATE SPECIFICITY;

EID: 79960264241     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00692.x     Document Type: Article

References (30)

1. Booven VD, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein T et al. Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics 2010;20:277-81.
2. Zhou SF, Zhou ZW, Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2009;278:165-88.
3. Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur J Clin Pharmacol 2003;59:221-5.
4. Christensen M, Andersson K, Dalen P, Mirghani RA, Muirhead GJ, Nordmark A et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003;73:517-28.
5. Yasar U, Bergengren FC, Tybring G, Dorado P, Llerena A, Sjoqvist F et al. Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 2002;71:89-98.
6. Sandberg M, Yasar U, Stromberg P, Hoog JO, Eliasson E. Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase. Br J Clin Pharmacol 2002;54:423-9.
7. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000;10:95-104.
8. Tan GM, Wu E, Lam YY, Yan BP. Role of warfarin pharmacogenetic testing in clinical practice. Pharmacogenomics 2010;11:439-48.
9. Tan B, Zhang YF, Chen XY, Zhao XH, Li GX, Zhong DF. The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. Eur J Clin Pharmacol 2010;66:145-51.
10. Pilotto A, Seripa D, Franceschi M, Scarcelli C, Colaizzo D, Grandone E et al. Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms. Gastroenterology 2007;133:465-71.
11. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005;77:1-16.
12. Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 2005;44:1209-25.
13. Yasar U, Eliasson E, Dahl ML, Johansson I, Sundberg MI, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999;254:628-31.
14. Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Sundberg MI. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol 2001;52:447-50.
15. Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO et al. CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 2004;60:337-42.
16. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M et al. Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther 2004;76:113-8.
17. Yasar U, Aklillu E, Canaparo R, Sandberg M, Sayi J, Roh HK et al. Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations. Eur J Clin Pharmacol 2002;58:555-8.
18. Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet 2009;10:124.
19. Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol 2003;56:653-7.
20. Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N et al. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009;37:1895-903.
21. Tanira MO, Mukhaini MKA, Hinai ATA, Balushi KAA, Ahmed IS. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose. Community Genet 2007;10:32-7.
22. Hamdy SI, Hiratsuka M, Narahara K, Enany ME, Moursi N, Ahmed MS et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol 2002;53:596-603.
23. Efrati E, Elkin H, Sprecher E, Krivoy N. Distribution of CYP2C9 and VKORC1 risk alleles for warfarin sensitivity and resistance in the Israeli population. Curr Drug Saf 2010;3:190-3.
24. McLellan RA, Oscarson M, Seidegard J, Evans DA, Sundberg MI. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997;7:187-91.
25. Evans DA, Krahn P, Narayanan N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. Pharmacogenetics 1995;5:64-71.
26. Nasu K, Kubota T, Ishizaki T. Genetic analysis of CYP2C9 polymorphism in a Japanese population. Pharmacogenetics 1997;7:405-9.
27. Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001;51:277-80.
28. Lee SS, Kim KM, Le HT, Yea SS, Cha IJ, Shin JG. Genetic polymorphism of CYP2C9 in a Vietnamese Kinh population. Ther Drug Monit 2005;27:208-10.
29. Klose THS, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996;6:341-9.
30. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 1996;6:429-39.